UT Dallas spinout Cersci has raised approximately $4m to advance its non-opioid painkiller into human clinical trials by the end of next year.
Cersci Therapeutics, a US-based non-opioid therapeutics spinout from University of Texas at Dallas (UTD), closed almost $4m in series A funding led by Hiawatha Education Foundation, Dallas Innovates reported today.
Hiawatha provided more than half of the series A capital, which also featured a North Texas investment consortium represented by Dallas craniofacial surgeon David Genecov.
Founded in 2015, Cersci is working on non-opioid painkillers to avoid the addictive side-effect of causing a high. The treatment prevents pain rather than masking…
